TRMT10A and central nervous system cancer: By analyzing the CGGA dataset, the expression of TRMT10A in the GBM group was significantly lower than that in the grade II glioma group, which was consistent with the downward trend of the above tRF-5s, suggesting that the m1G9 modification level of tRNA-ArgACG/CCG in the GBM group might not be the main factor affecting the stability of the above tRF-5s.